Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

Stock Information for SCYNEXIS Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About SCYNEXIS Inc.

Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant(TM) (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm(TM) (epinephrine) Sublingual Film
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
Aquestive Therapeutics to Present Crossover Study Data for Libervant(TM) (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.